Plain-English translation of NCT05172310 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Neoplasms research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of imaging scan called 68Ga-FAPI PET to help doctors better detect cancers in the pancreas, stomach, bile ducts, and ovaries. The new scan works by targeting special cells that grow around tumors, which may help doctors see cancer more clearly than traditional imaging. Researchers want to see if this scan can improve how accurately doctors diagnose and stage these cancers before surgery.
Cancers in these organs are often hard to detect early, and current imaging methods don't always show the full picture of how advanced the cancer is. This new imaging approach targets the supporting tissue around tumors, which could help doctors catch cancer earlier and plan better treatment.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would undergo the new 68Ga-FAPI PET imaging scan as part of your standard pre-surgical evaluation. The scan is similar to other PET scans you may have had, where you receive a radioactive tracer injection and then lie still while the scanner takes pictures. This would happen before your scheduled surgery, and the imaging results would help your surgical team better understand your cancer.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Sweden